|
|
|
| A controlled clinical study of Amisulpride and Aripiprazole in treatment of patients with negative symptoms of schizophrenia |
| WEI Li-qun |
| Department of Psychiatry,the Fourth People′s Hospital of Jingdezhen,Jiangxi Province,Jingdezhen 333000,China |
|
|
|
|
Abstract Objective To compare the efficacy and safety between Amisulpride and Aripiprazole in the treatment of patients with negative symptoms of schizophrenia.Methods A total of 80 Patients with negative symptoms of schizophrenia from May to December in 2017 treated in our hospital were selected as the research objects,all the patients were randomly divided into the control group and the study group,40 cases in each group.In the study group,the patients were treated with oral Amisulpride Tablets,and patients in the control group were treated with oral Aripiprazole.Both groups were treated for 8 weeks.The therapeutic effect,the positive and negative syndrome scale (PANSS)scores and adverse reactions were compared between two groups of patients before and after treatment 2,4 and 8 weeks.Results After 8 weeks of treatment,the total efficiency of the study group was 76.92%,and the the total efficiency of the control group was 75.67%,there was no significant difference between the two groups(P＞0.05).After 2 weeks of treatment,the negative factor score of the study group was significantly lower than before treatment and the control group,the differences were statistically significant(P＜0.05),while after 2 weeks of treatment,the negative factor score in the control group was not statistically significant compared with that before treatment(P＞0.05).After 4 weeks of treatment,the scores of negative factors in both groups were significantly lower than before treatment,and the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the study group(41.02%)was lower than that in the control group(54.05%),and the difference was statistically significant(P＜0.05).Conclusion The effect of Amisulprideis equivalent to Aripiprazolein treatment of patients with negative symptoms of schizophrenia,but Amisulpride has faster onset time,less adverse reactions,more safety and better compliance.It is worth popularizing the application.
|
|
|
|
|
|
| [1] |
曲鸿儒，高艳杰，毛富强，等.药物联合分散内观认知疗法对男性偏执型精神分裂症康复期疗效观察[J].中华行为医学与脑科学杂志，2012，21（1）：53-55.
|
| [2] |
Sicras-Mainar A，Mainaro J，Ruiz-Beato E，et al.Impact of negative symptoms on healthcare resource utilization and associatcdcostswithschizo-phrenia：apopulation-bascdstudy[J].BMC Psychiatry，2014，14（1）：225.
|
| [3] |
Azorin JM，Belzeaux R，Adida M.Negative sumptoms in schizophrenia：where wehave been and where we are heading[J].CNS Neurosci Ther，2014，20（9）：801-808.
|
| [4] |
Foussias G，Siddiqui I，Fervaha G，et al.Dissecting negative sump-toms in schizophrenia：Opportunities for translation intonew treatments[J].J Psychopharmacol，2015，29（2）：116-126.
|
| [5] |
聂所成，刘长成，张新风.氨磺必利对老年慢性精神分裂症患者生存质量和主观幸福感的影响[J].中国药物与临床，2016，16（9）：1335-1337.
|
| [6] |
刘艳艳，孙凌云.氨磺必利的药理学进展与临床应用评价[J].海峡药学，2016，28（7）：187-188.
|
| [7] |
戴云飞，肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较[J].临床精神医学杂志，2013，23（6）：426-427.
|
| [8] |
Hu TW.Perspectives：an international review of the national costestimates of mental illness 1990-2003[J].J Ment Health Policy Econ，2006，9（1）：3-13.
|
| [9] |
吴宇杰，李君，杜鹏，等.利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析[J].中国医药导报，2015，12（3）：100-102.
|
| [10] |
于晓东，季加翠，林正华，等.氨磺必利与利培酮治疗伴抑郁症状的精神分裂症对照研究[J].神医学杂志，2016，29（4）：277-279.
|
| [11] |
孙振晓，于相芬.氨磺必利的临床应用及其不良反应[J].精神医学杂志，2014，27（5）：392-397.
|
| [12] |
Konossa K，Rummel-Kluge C，Hunger H，et al.Amisulprideversus other atypical antipsychotics for schizophrenia[J].Cochrane Database Syst Rev，2010，20（1）：6624.
|
| [13] |
仇红杰.氨磺必利与阿立哌唑治疗首发精神分裂症的对照研究[J].中外医学研究，2014，12（21）：8-10.
|
| [14] |
胡亚兰.氨磺必利治疗精神分裂症阴性症状的对照研究[J].精神医学杂志，2014，27（2）：136-137.
|
| [15] |
徐海春，张昌，王春丽，等.氨磺必利与阿立哌唑治疗慢性精神分裂症的临床对照研究[J].中国医学创新，2016，13（10）：33-36.
|
| [16] |
刘晓.氨磺必利与阿立哌唑口腔崩解片治疗以阴性症状为主的精神分裂症的临床对照研究[J].四川精神卫生，2014，27（5）：416-418.
|
| [17] |
杨和增，朱华探，曾慧，等.氨磺必利对精神分裂症的影响[J].精神医学杂志，2013，26（3）：196-198.
|
|
|
|
